MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES

被引：0
|
作者：
Westerlund, Johanna [1 ]
Jokiranta, T. Sakari [1 ,2 ]
机构：
[1] United Medix Labs Ltd, Espoo, Finland
[2] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2012年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：325 / 325
页数：1
相关论文
共 50 条
  • [21] Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases
    Grinman, Ana B.
    de Souza, Maria das Gracas C.
    Bouskela, Eliete
    Carvalho, Ana Teresa P.
    de Souza, Heitor S. P.
    [J]. MEDICINE, 2020, 99 (10) : E19359
  • [22] Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
    Marona, Jose
    Rodrigues-Manica, Santiago
    Gomes, Joao Lagoas
    Lopes, Carina
    Iria, Ines
    Bernardes, Miguel
    Santos, Helena
    Tavares-Costa, Jose
    Madruga-Dias, Joao
    Pinto, Patricia
    Bernardo, Alexandra
    Maia, Sara
    Branco, Jaime
    Goncalves, Joao
    Pimentel-Santos, Fernando
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
    Karsten, Carley
    Grannas, Karin
    Bergman, Oskar
    Moverare, Robert
    Roforth, Matthew
    Willrich, Maria Alice V.
    Snyder, Melissa R.
    Yang, Yifei K.
    [J]. AAPS JOURNAL, 2024, 26 (05):
  • [24] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [25] Tolerating infliximab therapeutic drug monitoring without anti-drug antibodies - an argument for drug intolerant assays?
    Carlson, S.
    Evgeniou, V.
    Kok, K.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 894 - 895
  • [26] Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS™, Infliximab-abda) Using LabCorp Infliximab Assays for Drug Level and Anti-drug Antibodies
    Kelly, Chun
    Zonia, Garcia Gonzalez
    Jane, Yang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S25 - S25
  • [27] Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations
    Kim, J.
    Walshe, M.
    Borowski, K.
    Milgrom, R.
    Stempak, J.
    Lee, S. H.
    Croitoru, K.
    Silverberg, M. S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I933 - I934
  • [28] Measurement of functional blocade of TNF-alpha by anti-TNF G1 agents is a stronger predictor than trough levels and anti-drug antibodies: 3-year prospective clinical data
    Juillerat, Pascal
    Andrew, Peter
    Macpherson, James
    Slack, Emma
    Patuto, Nicola
    Cahenzli, Julia
    Schmid, Flavia
    Seibold, Frank
    McCoy, Kathy D.
    Macpherson, Andrew J.
    [J]. SWISS MEDICAL WEEKLY, 2015, 145 : S7 - S7
  • [29] Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies
    Demarzo, Maria Giulia
    Bodini, Giorgia
    Giuliana, Elisabetta
    Zentilin, Patrizia
    Giannini, Edoardo G.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) : 536 - 537
  • [30] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
12345